HPV infections: Basis of neoplastic transformation and related molecular tests

Current Pharmaceutical Design

Volumn 19, Issue 8, 2013, Pages 1371-1378

  French, Deborah ^a   Lorenzon, Laura ^b  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

E6; E7; HPV; Molecular test; p16

Indexed keywords

KI 67 ANTIGEN; PROTEIN P16;

CARCINOGENESIS; CELL PROLIFERATION; CYTOLOGY; HISTOLOGY; HUMAN; HUMAN PAPILLOMAVIRUS DNA TEST; IMMUNOHISTOCHEMISTRY; NUCLEIC ACID AMPLIFICATION; PAPILLOMAVIRUS INFECTION; PREDICTIVE VALUE; PRETECTUM; PRIORITY JOURNAL; REVIEW; SENSITIVITY AND SPECIFICITY; UTERINE CERVIX CANCER;

EID: 84876728634     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/1381612811319080003     Document Type: Review

References (70)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics 2002. CA Cancer J Clin 2005; 55, 74-108.
2. Kamangar F, Dores GM, Anderson WK. Patterns of cancer incidence, mortality and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol 2006; 24, 2137-50.
3. Stanley M. Pathology and epidemiology of HPV infection in females. Gynaecol Oncol 2010; 117 (Suppl 2): S5-10.
4. Schiffman M, Castle PE, Jeronimo J, Rodriguez AC, Wacholder S. Human papillomavirus and cervical cancer. Lancet 2007; 370: 890-907.
5. Munoz N, Bosch FX, de Sanjose S, et al. and the International Agency for Research on Cancer Multicenter Cervical Cancer Study Group. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003; 348: 518-27.
6. Sundström K, Eloranta S, Sparén P, et al. Prospective study of human papillomavirus (HPV) types, HPV persistence, and risk of squamous cell carcinoma of the cervix Cancer Epidemiol Biomarkers Prev 2010; 19 (10): 2469-78.
7. Gruppo Italiano di Screening del Cervicocarcinoma-GISCI. Raccomandazioni sul test HR-HPV come test di screening primario e rivisitazione del ruolo del Pap test. Available at: http://www.gisci.it/documenti-gisci.
8. Gruppo Italiano di Screening del Cervicocarcinoma-GISCI. Manuale del 2° livello. Raccomandazioni per la qualità nella diagnosi, terapia e follow up delle lesioni cervicali, nell'ambito dei programmi di screening. Available at: http://www.gisci.it/documentigisci.
9. Bosch FX, de SS. The epidemiology of human papillomavirus infection and cervical cancer. Dis Markers 2007; 23(4): 213-27.
10. von Knebel-Doeberitz M, Syrjanen KJ. Molecular markers: how to apply in practice. Gynecol Oncol 2006; 103: 18-20.
11. Woodman CBJ, Collins SI, Young LS. The natural history of cervical HPV infection: unresolved issues. Nature Rev Cancer 2007; 7: 11-22.
12. Moody CA, Laiminis La. Human papillomavirus oncoproteins: pathways to transformation. Nature Rev Cancer 2010; 10: 550-60.
13. Zhi-Ming Z, Backer CC. Papillomavirus genome structure, expression, and post-transcriptional regulation. Front Biosci 2006; 11: 2286-302.
14. Venuti A, Paolini F, Nasir L, et al. Papillomavirus E5: the smallest oncoprotein with many functions. Mol Cancer 2011; 10: 140.
15. Belleudi F, Leone L, Purpura V, Cannella F, Scrofani C, Torrisi MR. HPV16 E5 affects the KGFR/FGFR2b-mediated epithelial growth through alteration of the receptor expression, signaling and endocytic traffic. Oncogene 2011; 30 (50): 4963-76.
16. Cushieri K, Wentzensen N. HPV mRNA and p16 detection as biomarkers for the improved diagnosis of cervical neoplasia. Cancer Epidemiol Biomarkers Prev 2008; 17 (10): 2536-45.
17. Hudson JB, Bedell MA, McCance DJ, Laiminis LA. Immortalization and altered differentiation of human keratinocytes in vitro by the E6 and E7 open reading frames of human papillomavirus type 18. J Virol 1990; 64: 519-26.
18. Smits HL, van Gemen B, Schukkink R, et al. Application of the NASBA nucleic acid amplification method for the detection of human papillomavirus type 16 E6-E7 transcripts. J Virol Methods 1995; 54(1): 75-81.
19. Ratnam S, Coutlee F, Fontaine D, et al. Clinical performance of the PreTec HPV-Proofer E6/E7 mRNA assay in comparison with that of the Hybrid Capture 2 Test for identification of women at risk of cervical cancer. J Clin Microbiol 2010; 48: 2779-85.
20. Varnai AD, Bollmann M, Bankfalvi A, et al. Predictive testing of early cervical pre-cancer by detecting human papillomavirus E6/E7 mRNA in cervical cytologies up to high-grade squamous intraepithelial lesions: diagnostic and prognostic implications. Oncol Rep 2008; 19 (2): 457-65.
21. Cattani P, Zannini GF, Ricci C, et al. Clinical performance of Human Papillomavirus E6 and E7 mRNA testing for high-grade lesions of the cervix. J Clin Microbiol 2009; 47 (12): 3895-901.
22. Cushieri KS, Whitley MJ, Cubie HA. Human Papillomavirus type specific DNA and RNA persistence-implications for cervical disease progression and monitoring. J Med Virol 2004; 73: 65-70.
23. Molden T, Nygard JF, Kraus I, et al. Predicting CIN2 + when detecting HPV mRNA and DNA by PreTect HPV-Proofer and consensus PCR: a 2-year follow-up of women with ASCUS or LSIL Pap smear. Int J Cancer 2005; 114: 973-6.
24. Molden T, Kraus I, Karlsen F, Skomedal H, Nygård JF, Hagmar B. Comparison of Human Papillomavirus messanger RNA and DNA detection: a cross-sectional study of 4,136 women>30 years of age with a 2-years follow-up of high-grade squamous intraepithelial lesion. Cancer Epidemiol Biomarkers Prev 2005; 14(2): 367-72.
25. Sorbye SW, Arbyn M, Fismen S, Gutterberg T, Mortensen ES. HPV E6/E7 mRNA testing is more specific than cytology in postcolposcopy follow-up of women with negative cervical biopsy. Plos One 2011; 6: e26022.
26. Sorbye SW, Arbyn M, Fismen S, Gutterberg T, Mortensen ES. Triage of women with low-grade cervical lesions-HPV mRNA testing versus repeat cytology Plos One 2011; 6: e24083.
27. Sorbye SW, Fismen S, Gutterberg T, Mortensen ES. Triage of women with minor cervical lesions: data suggesting a "test and treat" approach for HPV E6/E7 mRNA testing. Plos One 2010; 5: e12724.
28. Andersson E, Kärrberg C, Rådberg T, et al. Type-specific human papillomavirus E6/E7 mRNA detection by real-time PCR improves identification of cervical neoplasia. J Clin Microbiol 2011; 49 (11): 3794-9.
29. Benevolo M, Terrenato I, Mottolese M, et al. Diagnostic and prognostic validity of the human papillomavirus E6/E7 mRNA test in cervical cytological samples of HC2-positive patients. Cancer Causes Control 2011; 22: 869-875
30. Benevolo M, Vocaturo A, Caraceni D, et al. Sensitivity, specificity, and clinical value of human papillomavirus (HPV) E6/E7 mRNA assay as a triage test for cervical cytology and HPV DNA test. J Clin Microbiol 2011; 49(7): 2643-50.
31. Tropé A, Jonassen CM, Sjøborg KD, et al. Role of high-risk human papillomavirus (HPV) mRNA testing in the prediction of residual disease after conisation for high-grade cervical intraepithelial neoplasia. Gynecol Oncol 2011; 123: 257-62.
32. Hovland S, Muller S, Skomedal H, et al. E6/E7 mRNA expression analysis: a test for the objective assessment of cervical adenocarci noma in clinical prognostic procedure. Int J Oncol 2010; 36: 1533-9.
33. Ho GY, Bierman R, Beardsley L, Chang CJ, Burk RD. Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med 1998; 338 (7): 423-8.
34. Moscicki AB, Shiboski S, Hills NK, et al. Regression of low-grade squamous intra-epithelial lesions in young women. Lancet 2004; 364 (9446): 1678-83.
35. Frega A, Lorenzon L, Giovagnoli MR, et al. Prognostic implication of high risk human papillomavirus E6 and E7 mRNA in patients with intraepithelial lesions of the cervix in relationship to age. Int J Immunopathol Pharmacol 2011; 24(2): 461-70.
36. Waldstrøm M, Ornskov D. Clinical performance of a human papillomavirus messenger RNA test (Aptima HPV Assay) on residual material from archived 3-year-old PreservCyt samples with lowgrade squamous intraepithelial lesion. Arch Pathol Lab Med 2011; 135: 1052-1056.
37. Dockter J, Schroder A, Eaton B, et al. Analytical characterization of the APTIMA HPV Assay. J Clin Virol 2009; 45 (S1): S39-S47.
38. Getman D, Aiyer A, Dockter J, Giachetti C, Zhang F, Ginocchio CC. Efficiency of the APTIMA HPV Assay for detection of HPV RNA and DNA targets. J Clin Virol 2009; 45 (S1): S49-S54.
39. Monsonego J, Hudgens MG, Zerat L, et al. Evaluation of oncogenic human papillomavirus RNA and DNA tests with liquid-based cytology in primary cervical cancer screening: the FASE study. Int J Cancer 2011; 129: 691-701.
40. Monsonego J, Hudgens MG, Zerat L, Zerat JC, Syrjänen K, Smith JS. Risk assessment and clinical impact of liquid-based cytology, oncogenic human papillomavirus (HPV) DNA and mRNA testing in primary cervical cancer screening (the FASE study). Gynecol Oncol 2012; 125: 175-80.
41. Dockter J, Schroder A, Hill C, Guzenski L, Monsonego J, Giachetti C. Clinical performance of the APTIMA HPV Assay for the detection of high-risk HPV and high-grade cervical lesions. J Clin Virol 2009; 45 (S1): S55-61.
42. Waldstrom M, Ornskov D. Comparison of the clinical performance of an HPV mRNA test and an HPV DNA test in triage of atypical squamous cells of undetermined significance (ASC-US). Cytopathology. 2011 Sep 20. doi: 10.1111/j.1365-2303.2011.00923.x. [Epub ahead of print].
43. Klaes R, Friedrich T, Spitkovsky D, et al. Overexpression of p16(INK4A) as a specific marker for dysplastic and neoplastic epithelial cells of the cervix uteri. Int J Cancer 2001; 92(2): 276-84.
44. Longatto Filho A, Utagawa ML, Shirata NK, et al. Immunocytochemical expression of p16INK4A and Ki-67 in cytologically negative and equivocal pap smears positive for oncogenic human papillomavirus. Int J Gynecol Pathol 2005; 24(2): 118-24.
45. Bibbo M, Klump WJ, DeCecco J, Kovatich AJ. Procedure for immunocytochemical detection of P16INK4A antigen in thin-layer, liquid-based specimens. Acta Cytol 2002; 46(1): 25-9.
46. Sahebali S, Depuydt CE, Segers K, et al. P16INK4a as an adjunct marker in liquid-based cervical cytology. Int J Cancer 2004; 108(6): 871-6.
47. Trunk MJ, Dallenbach-Hellweg G, Ridder R, et al. Morphologic Characteristics of p16INK4a-Positive Cells in Cervical Cytology Samples. Acta Cytol 2004; 48(6): 771-82.
48. Benevolo M, Vocaturo A, Mottolese M, et al. Clinical role of p16INK4a expression in liquid-based cervical cytology: correlation with HPV testing and histologic diagnosis. Am J Clin Pathol 2008; 129(4): 606-612.
49. Yildiz IZ, Usubütün A, Firat P, Ayhan A, Küçükali T. Efficiency of immunohistochemical p16 expression and HPV typing in cervical squamous intraepithelial lesion grading and review of the p16 literature. Pathol Res Pract 2007; 203(6): 445-9.
50. Wentzensen N, Bergeron C, Cas F, Vinokurova S, von Knebel Doeberitz M. Triage of women with ASCUS and LSIL cytology: use of qualitative assessment of p16INK4a positive cells to identify patients with high-grade cervical intraepithelial neoplasia. Cancer 2007; 111(1): 58-66.
51. Nieh S, Chen SF, Chu TY, Lai HC, Fu E. Expression of p16 INK4A in Papanicolaou smears containing atypical squamous cells of undetermined significance from the uterine cervix. Gynecol Oncol 2003; 91(1): 201-8.
52. Nieh S, Chen SF, Chu TY, et al. Is p16(INK4A) expression more useful than human papillomavirus test to determine the outcome of atypical squamous cells of undetermined significancecategorizedPap smear? A comparative analysis using abnormal cervical smears with follow-up biopsies. Gynecol Oncol 2005; 97(1): 35-40.
53. Murphy N, Ring M, Killalea AG, et al. p16INK4A as a marker for cervical dyskaryosis: CIN and cGIN in cervical biopsies and Thin-Prep smears. J Clin Pathol 2003; 56(1): 56-63.
54. Murphy N, Heffron CC, King B, et al. p16INK4A positivity in benign, premalignant and malignant cervical glandular lesions: a potential diagnostic problem. Virchows Arch 2004; 445(6): 610-5.
55. Murphy N, Ring M, Heffron CC, et al. p16INK4A, CDC6, and MCM5: predictive biomarkers in cervical preinvasive neoplasia and cervical cancer. J Clin Pathol 2005; 58(5): 525-34.
56. Benevolo M, Mottolese M, Marandino F, et al. Immunohistochemical expression of p16(INK4a) is predictive of HR-HPV infection in cervical low-grade lesions. Mod Pathol 2006; 19(3): 384-91.
57. Wang SS, Trunk M, Schiffman M, et al. Validation of p16INK4a as a marker of oncogenic human papillomavirus infection in cervical biopsies from a population-based cohort in Costa Rica. Cancer Epidemiol Biomarkers Prev 2004; 13(8): 1355-60.
58. Gertych A, Joseph AO, Walts AE, Bose S. Automated Detection of Dual p16/Ki67 Nuclear Immunoreactivity in Liquid-Based Pap Tests for Improved Cervical Cancer Risk Stratification. Ann Biomed Eng 2012; 40(5): 1192-204.
59. Baak JP, Kruse AJ, Robboy SJ, Janssen EA, van DB, Skaland I. Dynamic behavioural interpretation of cervical intraepithelial neoplasia with molecular biomarkers. J Clin Pathol 2006; 59(10): 1017-28.
60. Akpolat I, Smith DA, Ramzy I, Chirala M, Mody DR. The utility of p16INK4a and Ki-67 staining on cell blocks prepared from residual thin-layer cervicovaginal material. Cancer 2004; 102(3): 142-9.
61. Szarewski A, Ambroisine L, Cadman L, et al. Comparison of predictors for high-grade cervical intraepithelial neoplasia in women with abnormal smears. Can Epidemiol Biomarkers Prev 2008; 17(11): 3033-42.
62. Szarewski A, Mesher D, Cadman L, et al. A comparison of seven tests for high grade cervical intraepithelial neoplasia in women with abnormal smears: the Predictors 2 study. J Clin Microbiol. 2012 Mar 14. [Epub ahead of print].
63. Ratnam S, Coutlee F, Fontaine D, et al. Aptima HPV E6/E7 mRNA test is as sensitive as Hybrid Capture 2 Assay but more specific at detecting cervical precancer and cancer. J Clin Microbiol 2011; 49 (2): 557-64.
64. Ovestad IT, Vennestrøm U, Andersen L, et al. Comparison of different commercial methods for HPV detection in follow-up cytology after ASCUS/LSIL, prediction of CIN2-3 in follow up biopsies and spontaneous regression of CIN2-3. Gynecol Oncol 2011; 123: 278-83.
65. Burger EA, Kornør H, Klemp M, Lauvrak V, Kristiansen IS. HPV mRNA tests for the detection of cervical intraepithelial neoplasia: a systematic review. Gynecol Oncol 2011; 120: 430-8.
66. Ronco G, Giorgi-Rossi P, Carozzi F, et al. Efficacy of human papilloma virus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: a randomised controlled trial. Lancet Oncol 2010; 11 (3): 249-57.
67. Tonon SA, Picconi MA, Bos PD, et al. Physical status of the E2 human papilloma virus 16 viral gene in cervical preneoplastic and neoplastic lesions. J Clin Virol 2001; 21: 129-34.
68. Nagao S, Yoshinouchi M, Miyagi Y, et al. Rapid and sensitive detection of physical status of Human Papillomavirus type 16 DNA by quantitative Real-Time PCR. J Clin Microbiol 2002; 40: 863-7.
69. Hafner N, Driesch C, Gajda M, et al. Integration of the HPV16 genome does not invariably result in high levels of viral oncogene transcripts. Oncogene 2008; 27: 1610-7.
70. Lorenzon L, Mazzetta F, Venuti A, Frega A, Torrisi MR, French D. In vivo HPV 16 E5 mRNA: expression pattern in patients with squamous intra-epithelial lesions of the cervix. J Clin Virol 2011; 52(2): 79-83.